Stockscreener 앱 받기
184.71
0.49%
0.90
전일 마감가:
$183.81
열려 있는:
$184
하루 거래량:
331.61K
Relative Volume:
0.91
시가총액:
$19.68B
수익:
$3.32B
순이익/손실:
$-860.46M
주가수익비율:
-22.20
EPS:
-8.32
순현금흐름:
$-1.04B
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
-4.70%
1년 성능:
+19.09%
1일 변동 폭
$183.91
$187.42
1주일 범위
$183.91
$187.42
52주 변동 폭
$126.97
$248.16
Beigene Ltd Adr Stock (BGNE) Company Profile
명칭
Beigene Ltd Adr
전화
13459494123
주소
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
BGNE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BGNE
Beigene Ltd Adr
|
184.71 | 19.68B | 3.32B | -860.46M | -1.04B | -8.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-03 | 재개 | Morgan Stanley | Overweight |
| 2024-09-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-06 | 재개 | JP Morgan | Overweight |
| 2023-09-12 | 개시 | Macquarie | Outperform |
| 2023-08-17 | 개시 | Jefferies | Buy |
| 2023-07-17 | 개시 | Citigroup | Buy |
| 2023-06-30 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 개시 | Daiwa Securities | Buy |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-10-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 재개 | JP Morgan | Overweight |
| 2022-03-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 개시 | Deutsche Bank | Buy |
| 2021-10-12 | 개시 | Bernstein | Outperform |
| 2021-10-06 | 업그레이드 | CLSA | Underperform → Buy |
| 2021-03-08 | 개시 | China Renaissance | Buy |
| 2021-03-01 | 다운그레이드 | CLSA | Outperform → Underperform |
| 2020-11-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-06 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2020-07-10 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-03-13 | 업그레이드 | Macquarie | Underperform → Neutral |
| 2020-02-18 | 재개 | Goldman | Buy |
| 2020-01-17 | 업그레이드 | CLSA | Outperform → Buy |
| 2020-01-17 | 재개 | Morgan Stanley | Overweight |
| 2019-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-12-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-11-19 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-13 | 다운그레이드 | CLSA | Buy → Outperform |
| 2019-11-04 | 재확인 | Maxim Group | Buy |
| 2019-06-04 | 개시 | Bernstein | Outperform |
| 2019-05-10 | 업그레이드 | CLSA | Outperform → Buy |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-01-04 | 다운그레이드 | CLSA | Buy → Outperform |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-09-25 | 개시 | Leerink Partners | Outperform |
| 2018-05-17 | 재확인 | Maxim Group | Buy |
모두보기
Beigene Ltd Adr 주식(BGNE)의 최신 뉴스
Beigene's global head of R&D sells $1.29m in shares - Investing.com India
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
BeiGene stock soars to 52-week high of $258.66 amid robust growth - Investing.com India
BeiGene's president sells $12.5 million in company shares - Investing.com
Beigene's Wang Xiaodong sells $9.4 million in shares - Investing.com India
Beigene's Wang Xiaodong sells $9.4 million in shares By Investing.com - Investing.com South Africa
CCBI Adds BEIGENE's TP to $179 for Better Fundamentals This Yr - AASTOCKS.com
BEIGENE (06160.HK) Climbs 6% in Early Session, Expects to Achieve Positive Operating Income This Yr - AASTOCKS.com
Beigene director Wang Xiaodong sells $7.37 million in shares - Investing.com
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com India
Beigene directors sell shares worth $194.2 million - Investing.com
Beigene president Wu Xiaobin reports $120,894 sale of economic interest By Investing.com - Investing.com South Africa
Beigene president Wu Xiaobin reports $120,894 sale of economic interest - Investing.com
Beigene sees $3.57 billion stock sale by Hillhouse Investment By Investing.com - Investing.com South Africa
Beigene sees $274 million stock sale by Hillhouse Investment By Investing.com - Investing.com
AGFA Gevaert NV (AGFB.BR) Stock Price, News & Analyst Forecast - eToro
Morgan Stanley increases BeiGene stock target on drug prospects - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Beigene's Wang Xiaodong sells shares worth $9.19 million - Investing.com
BeiGene stock outlook positive as Bernstein lifts price target, keeps Market Perform - Investing.com
China ADRs have increased to the largest share since late 2021 – GS - MSN
BeiGene settles patent litigation, extends BRUKINSA exclusivity - Investing.com
10 Biggest Biotechnology Companies - Investopedia
BeiGene announces name change to BeOne Medicines Ltd. - Investing.com
BeiGene shares lift on raised price target to $260 from $254 - Investing.com
UBS Raises BeiGene (BGNE.US) TP to US$289.7 as 3Q Results Beat - AASTOCKS.com
BeiGene shares fall despite better-than-expected Q3 results - Investing.com
BeiGene announces passing of board member Donald Glazer - Investing.com
BEIGENE Senior Staff Reportedly Investigated, but Not Related to Firm Operations - AASTOCKS.com
Beigene Ltd Adr (BGNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.20%
2.04%
자본화:
|
볼륨(24시간):